Maxim Group Sticks to Their Buy Rating for Virpax Pharmaceuticals (VRPX)

Maxim Group analyst Naz Rahman maintained a Buy rating on Virpax Pharmaceuticals (VRPXResearch Report) yesterday and set a price target of $4.00. The company’s shares opened today at $0.83.

Rahman covers the Healthcare sector, focusing on stocks such as Clene, Quoin Pharmaceuticals, and scPharmaceuticals. According to TipRanks, Rahman has an average return of 4.0% and a 36.07% success rate on recommended stocks.

Virpax Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.

See the top stocks recommended by analysts >>

Based on Virpax Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.52 million. In comparison, last year the company had a GAAP net loss of $5.14 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.

Read More on VRPX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More